
    
      This trial assessed CS-1008 administered in combination with paclitaxel/carboplatin to
      patients with Stage IIIC or IV ovarian cancer who had suboptimal debulking surgery with
      residual measurable/evaluable disease and who had not received prior therapy for their
      disease. The effect of this first-line treatment in patients was assessed by complete
      response rate.
    
  